Skip to main content
M

Maxigen Biotech Inc. — Investor Relations & Filings

Ticker · 1783 TW Manufacturing
Open in API
Filings indexed 1,659 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country TW Taiwan
Listing TW 1783

About Maxigen Biotech Inc.

https://www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_1783_AI1.pdf
Regulatory Filings
2026-05-05 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 1% confidence The document is a detailed “Consolidated Statement of Changes in Equity” for the first quarter of the fiscal year, showing opening balances, net income, other comprehensive income, share-based payments, and ending balances for the quarter and prior year quarter. It contains substantive financial statements for a period shorter than a full year, fitting the definition of an Interim/Quarterly Report rather than just an announcement or earnings summary. Q1 2026
2026-04-29 English
115年第1季現金流量表
Interim / Quarterly Report Classification · 1% confidence The document presents the consolidated cash flow statement for the company’s first quarter (January 1 to March 31) with detailed figures for operating, investing, and financing activities. It is substantive financial data for an interim period rather than merely an announcement or link to a report. Therefore, it constitutes part of an interim/quarterly report. Q1 2026
2026-04-29 Chinese
115年第1季綜合損益表
Interim / Quarterly Report Classification · 1% confidence The document is a full consolidated comprehensive income statement for the first quarter (ROC Year 115 Q1), showing detailed line‐by‐line financial statement figures (revenues, expenses, profit, EPS, etc.) rather than just headline highlights or a simple announcement. It clearly is substantive interim financial reporting for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report. Q1 2026
2026-04-29 Chinese
115年第1季資產負債表
Interim / Quarterly Report Classification · 1% confidence The document is a detailed consolidated balance sheet (合併資產負債表) for the first quarter (115年第1季) with full asset, liability, and equity breakdowns and actual financial statement line items. It clearly contains substantive financial data for a period shorter than a full fiscal year (a seasonal report), not merely an announcement or link to a report. This matches the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-04-29 Chinese
董事會決議股利分派
Notice of Dividend Amount Classification · 1% confidence The text is a public announcement by the board of directors detailing the dividend distribution for the fiscal year 114, including cash dividend per share, total amount, and record dates. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-04-28 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.